Overview

Inductive Toripalimab and Paclitaxel/Cisplatin on Pathological Response in Oral Squamous Cell Carcinoma Patients

Status:
Active, not recruiting

Trial end date:
2023-09-30

Target enrollment:

Participant gender:

Summary

The aim of this study is to use the combination of immune checkpoint inhibitor of Toripalimab, and chemotherapy agents of TP, as an inductive therapy to treat the patients with locally advanced OSCC, followed with radical surgery and post-operative radiotherapy/chemoradiotherapy, the major pathological response and safety will be evaluated as the primary surrogate endpoints, the 2-year survival rate and local recurrence rate will be the second endpoints.

Phase:

Phase 1

Details

Lead Sponsor:

Shanghai Jiao Tong University School of Medicine

Treatments:

Cisplatin
Paclitaxel